Cargando…

Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performance Improvement and Future Direction

We conducted a pilot newborn screening (NBS) study for Pompe disease (PD) and mucopolysaccharidosis type I (MPS I) in the multiethnic population of Georgia. We screened 59,332 infants using a two-tier strategy of flow injection tandem mass spectrometry (FIA-MSMS) enzyme assays. The first tier of tes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hall, Patricia L., Sanchez, Rossana, Hagar, Arthur F., Jerris, S. Caleb, Wittenauer, Angela, Wilcox, William R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021244/ https://www.ncbi.nlm.nih.gov/pubmed/32064362 http://dx.doi.org/10.3390/ijns6010002

Ejemplares similares

Newborn Screening for X-Linked Adrenoleukodystrophy in Georgia: Experiences from a Pilot Study Screening of 51,081 Newborns
por: Hall, Patricia L., et al.
Publicado: (2020)

Post-Analytical Tools for the Triage of Newborn Screening Results in Follow-up Can Reduce Confirmatory Testing and Guide Performance Improvement
por: Hall, Patricia L., et al.
Publicado: (2020)

Harmonization of Newborn Screening Results for Pompe Disease and Mucopolysaccharidosis Type I
por: Dorley, M. Christine, et al.
Publicado: (2023)

Second Tier Molecular Genetic Testing in Newborn Screening for Pompe Disease: Landscape and Challenges
por: Smith, Laurie D., et al.
Publicado: (2020)

Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I
por: Peck, Dawn S., et al.
Publicado: (2020)

A rapid and non-invasive proteomic analysis using DBS and buccal swab for multiplexed second-tier screening of Pompe disease and Mucopolysaccharidosis type I
por: Zhang, Tong, et al.
Publicado: (2022)

Newborn Screening for Pompe Disease
por: Sawada, Takaaki, et al.
Publicado: (2020)

Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases
por: Belfiore, Maria Paola, et al.
Publicado: (2020)

Performance of Expanded Newborn Screening in Norway Supported by Post-Analytical Bioinformatics Tools and Rapid Second-Tier DNA Analyses
por: Tangeraas, Trine, et al.
Publicado: (2020)

Development of Newborn Screening for Pompe Disease
por: Hwu, Wuh-Liang, et al.
Publicado: (2020)

Newborn screening for Pompe disease in Italy: Long-term results and future challenges
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

The Combined Impact of CLIR Post-Analytical Tools and Second Tier Testing on the Performance of Newborn Screening for Disorders of Propionate, Methionine, and Cobalamin Metabolism
por: Gavrilov, Dimitar K., et al.
Publicado: (2020)

Newborn Screening for Pompe Disease: Pennsylvania Experience
por: Ficicioglu, Can, et al.
Publicado: (2020)

Muscle ultrasound: A useful tool in newborn screening for infantile onset pompe disease
por: Hwang, Hsuen-En, et al.
Publicado: (2017)

The Impact of Post-Analytical Tools on New York Screening for Krabbe Disease and Pompe Disease
por: Martin, Monica M., et al.
Publicado: (2020)

Performance of the Four-Plex Tandem Mass Spectrometry Lysosomal Storage Disease Newborn Screening Test: The Necessity of Adding a 2nd Tier Test for Pompe Disease
por: Chiang, Shu-Chuan, et al.
Publicado: (2018)

Establishing Pompe Disease Newborn Screening: The Role of Industry
por: Keutzer, Joan M.
Publicado: (2020)

Current status of newborn screening for Pompe disease in Japan
por: Sawada, Takaaki, et al.
Publicado: (2021)

Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update
por: Burton, Barbara K., et al.
Publicado: (2020)

Current Practices for U.S. Newborn Screening of Pompe Disease and MPSI
por: Ames, Elizabeth G., et al.
Publicado: (2020)

The First Year Experience of Newborn Screening for Pompe Disease in California
por: Tang, Hao, et al.
Publicado: (2020)

Lessons Learned from Pompe Disease Newborn Screening and Follow-up
por: Klug, Tracy L., et al.
Publicado: (2020)

Newborn Screening for Pompe Disease in Illinois: Experience with 684,290 Infants
por: Burton, Barbara K., et al.
Publicado: (2020)

Future approach to tier-0 extension
por: Jones, B, et al.
Publicado: (2017)

CMS Tier-0: Preparing for the future
por: Hufnagel, Dirk
Publicado: (2012)

A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan
por: Lin, Shuan-Pei, et al.
Publicado: (2013)

Newborn Screening for Mucopolysaccharidosis I: Moving Forward Learning from Experience
por: Clarke, Lorne A., et al.
Publicado: (2020)

Newborn screening for pompe disease? a qualitative study exploring professional views
por: van El, Carla G, et al.
Publicado: (2014)

The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan
por: Chiang, Shu-Chuan, et al.
Publicado: (2020)

Muscle ultrasound in patients with late-onset Pompe disease identified by newborn screening
por: Jackson, David G., et al.
Publicado: (2023)

LHC Networking to the Tier-1's, Present and Future
por: Foster, David
Publicado: (2008)

A Tiered Analytical Approach for Investigating Poor Quality Emergency Contraceptives
por: Monge, María Eugenia, et al.
Publicado: (2014)

Combining newborn metabolic and DNA analysis for second-tier testing of methylmalonic acidemia
por: Peng, Gang, et al.
Publicado: (2018)

Genomic Sequencing as a First-Tier Screening Test and Outcomes of Newborn Screening
por: Chen, Ting, et al.
Publicado: (2023)

The Future of Analytics
por: Darnell, Dan, et al.
Publicado: (2020)

Pompes turbomoleculaires
por: Versolatto, B
Publicado: (1982)

Is Newborn Screening the Ultimate Strategy to Reduce Diagnostic Delays in Pompe Disease? The Parent and Patient Perspective
por: Saich, Raymond, et al.
Publicado: (2020)

At-Risk Testing for Pompe Disease Using Dried Blood Spots: Lessons Learned for Newborn Screening
por: Lukacs, Zoltan, et al.
Publicado: (2020)

Newborn Screening for Lysosomal Storage Diseases: Methodologies, Screen Positive Rates, Normalization of Datasets, Second-Tier Tests, and Post-Analysis Tools
por: Gelb, Michael H.
Publicado: (2018)

Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy
por: Burlina, Alberto B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vt0qdmb7nrjvfun21pmo741mnv